Key Highlights

  • Surgery Partners (NASDAQ:SGRY) gained about 14% on November 9, 2026, ending near USD 25.98 once its agreed acquirer improved terms to counter a competing offer.
  • HealthSpan, an affiliate of Bon Secours Mercy Health, raised the cash price to USD 25.00 a share from USD 23.50, a deal worth up to roughly USD 6 billion.
  • Should closing be delayed, a payment of as much as USD 1.61 per share could be added, lifting the maximum to USD 26.61 per share.
  • A third party, not named, had offered USD 28.00 a share in cash, but the special committee judged that bid as not superior.

What Changed in the Revised Pact

Surgery Partners (NASDAQ:SGRY) operates over 200 surgical facilities spread across 30 states, mostly ambulatory surgery centres where outpatient procedures cost less than in hospitals. In late October 2026 the company agreed to a sale to HealthSpan at USD 23.50 a share, implying an Enterprise value near USD 5.7 billion. The amendment disclosed November 9 raises the figure to USD 25.00, about 6.4% above the original. A delay-compensation feature was also added: when shareholders approve before March 1, 2027 yet the deal has not closed, holders receive monthly amounts equal to a 10% yearly rate on USD 25.00, which reaches USD 1.61 per share if closing slips to October 23, 2027. The biggest shareholder, with close to 39%, will support the transaction and keep its holding inside the merged company rather than cashing out.

Reasons the Board Declined the USD 28 Approach

The competing approach arrived November 3 and was updated November 8, proposing USD 28.00 in cash, approximately 12% beyond the reset HealthSpan figure. An independent special committee, working with its own advisers, unanimously determined the proposal fell short of being superior. Its concerns centred on a slower and less dependable path to closing, heavier regulatory hazards and softer contractual safeguards. Management argues the HealthSpan agreement offers regulatory certainty and a quick finish, with completion projected for the first quarter of 2027, and the board stood by its recommendation. Financing will combine existing cash with newly committed debt. The stock is telling its own tale: shares ended near USD 25.98, above the contracted price, a pattern suggesting some participants expect more bidding or a return by the challenger with better conditions.

Exposure for Investors Buying Above the Offer

Purchasing above the agreed price brings its own danger. Should the challenger neither raise nor firm its position, a buyer near USD 26 would collect USD 25.00 along with any delay payment, which means a modest loss before those payments unless closing drags on. Because the largest Shareholder backs the present transaction, that holder's vote will carry considerable influence. Regulatory scrutiny of healthcare deals has become stricter, so an extended review would generate delay payments while pushing back the cash. On the flip side, a firm and fully funded counteroffer might prompt the board to revisit its position. Monitor for any renewed rival proposal, the date of the shareholder vote and filings with regulators in coming months. Individual tax position and the timing of cash receipts also deserve attention before any decision.

Where Things Stand

Surgery Partners rose about 14% on November 9, 2026 as HealthSpan increased its bid to USD 25.00 a share, with delay payments capping out at USD 1.61, while the board said a rival USD 28.00 offer was inferior. A close near USD 25.98 hints that traders still expect a higher price. The challenger's next step, the shareholder ballot and regulatory clearances will settle the matter.